TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06944522: A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Sponsor: BlueRock Therapeutics · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 102 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$4,242,392

Rescue Site Savings

+$2,809,896

Unlock Full NCT06944522 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06944522 Rescue Dossier →